Research
The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant
Nature ·
The Brief
- A study published in a Nature subject feed examines how CYP3A5 genotype affects tacrolimus pharmacokinetics in children after heart transplant.
- The only source available is the article title and link; no summary or findings were provided.
- Specific results, sample sizes and dosing conclusions cannot be confirmed from the provided sources.
Why it matters
Tacrolimus is a key immunosuppressant after transplant and its blood levels vary widely between patients, so genotype-based dosing research in children is of interest to pharmacology and clinical science readers.
Who’s affected
- clinicians and pharmacologists treating paediatric heart transplant patients
- pharmacogenetics researchers
- #pharmacogenetics
- #tacrolimus
- #heart transplant
- #paediatrics
- #cyp3a5
Timeline
Article listed in nature.com subject feed
Medical research : nature.com subject feeds
The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant